FDA Brief

Warning letters Drugs

FDA warning letter to

Guangdong Renhe Guozhuang Biotechnology Co., Ltd.

High riskIssued Dec 16, 2025Posted Dec 23, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.

What happened

FDA reviewed records the company submitted after FDA's April 28, 2025 request under section 704(a)(4) of the FD&C Act and later correspondence. FDA found significant CGMP violations: no adequate batch release testing for identity, strength, and objectionable microorganisms; no component identity testing for high-risk components; and no process validation. FDA placed all drugs and drug products offered for import from the firm on Import Alert 66-40 on November 12, 2025.

What FDA found

  1. The firm did not test each batch for identity and strength of active ingredients, or for objectionable microorganisms, before release.

    21 CFR 211.165(a) and 211.165(b)
  2. The firm did not perform at least one identity test on each incoming component, including high-risk components.

    21 CFR 211.84(d)(1)
  3. The firm did not establish adequate written production and process control procedures and had not performed process validation.

    21 CFR 211.100(a)

What FDA wants

FDA tells the firm to respond in writing within 15 working days describing corrective actions and steps to prevent recurrence. FDA also requests specific testing data, including component test results within 30 calendar days, risk assessments, process validation plans, and a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drugs from this manufacturer
  • U.S. importers and distributors of OTC drug products
  • suppliers of drug components to this manufacturer

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk